权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Outcomes Research in Rheumatic Diseases

风湿性疾病的结果研究

基本信息

批准号：
10254297
负责人：
DINESH KHANNA
金额：
$ 13.28万
依托单位：
UNIVERSITY OF MICHIGAN AT ANN ARBOR
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-09-01 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10254297
关键词：
Address Advocate Antibody-drug conjugates Area Autoimmunity Award Blood Charge Clinical Clinical Research Clinical Trials Design Computerized Medical Record Consensus Cutaneous Data Development Diffuse Discipline Documentation Dose Double-Blind Method Ensure Exercise Faculty Fostering Foxes Funding Future Goals Grant Growth Health Personnel Immune Tolerance Information Resources Management Information Systems Institution International Internet Interstitial Lung Diseases Journals Leadership Link Measurement Measures Medical Students Medicine Mentors Michigan Molecular Profiling National Institute of Allergy and Infectious Disease National Institute of Arthritis and Musculoskeletal and Skin Diseases Outcome Measure Outcomes Research Patient Outcomes Assessments Patient-Focused Outcomes Patients Peer Review Phase Pilot Projects Placebos Postdoctoral Fellow Protocols documentation Publishing Randomized Controlled Trials Reporting Research Research Personnel Research Project Grants Research Support Research Training Rheumatism Role Safety Scleroderma Secure Self Efficacy Self Management Skin Systemic Scleroderma T-Lymphocyte TNFRSF8 gene Techniques Time Training Training Programs United States National Institutes of Health Universities base career clinical practice comparative effectiveness study improved indexing interest next generation patient oriented research patient-clinician communication point of care preservation primary outcome professor programs prospective recruit response safety study self-management program skills subcutaneous undergraduate student

项目摘要

Project Summary/Abstract Outcomes research in rheumatic diseases Dr. Dinesh Khanna is a professor of medicine at the University of Michigan (UM) and director of the UM Scleroderma Program. He seeks the extension of the K24 Mid-Career Investigator Award in Patient-Oriented Research (POR) to continue this successful research program while dedicating significant time for mentoring the next generation of undergraduates, medical students, residents, clinical and post-doctoral fellows, and junior faculty trainees. The goals of the K24 renewal application are to support the candidate's continued impact as a mentor and assume leadership roles in collaborative POR programs, to continue the growth of a research training program for POR at the UM, and to recruit new mentees who are interested in POR. Since the successful funding of the initial K24 grant, the candidate has actively mentored trainees and junior faculty on different POR projects who have published in peer-reviewed journals and received independent funding. The candidate has launched successful collaborative links with other disciplines and institutions in the pursuit of program excellence, and there is strong institutional support to create this program. The K24 grant would preserve 30% of the candidate's effort and relieve future clinical and administrative responsibilities. A diverse portfolio of currently funded research opportunities exists for future trainees in POR. The research proposed includes four current projects and one new project addressing POR areas of patient reported outcomes, outcome measures, and clinical trial design. The currently funded studies include: 1) Taking charge of systemic sclerosis: Improving patient outcomes through self-management (funded by PCORI); 2) Development of a systemic sclerosis-associated interstitial lung disease combined response index (R01, funded by NIH/NIAMS); 3) An investigator-initiated, multicenter international phase II pilot study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis—a double-blind, placebo-controlled, randomized controlled trial (funded by NIH/NIAID, University of Michigan Autoimmunity Center of Excellence and Bristol Myers Squibb); and 4) A dose escalation safety study of brentuximab vedotin in diffuse dutaneous Systemic Sclerosis (funded by NIH/NIAID/Immune Tolerance Network). The aim of the new proposed study is to implementation the NIH Patient-Reported Outcomes Measurement Information System (PROMIS®) in clinical practice using a pilot cluster randomized controlled trial.

项目总结/文摘